Urinary prednisolone excretion is a determinant of serum hepcidin levels in renal transplant recipients by Eisenga, Michele F. et al.
  
 University of Groningen
Urinary prednisolone excretion is a determinant of serum hepcidin levels in renal transplant
recipients
Eisenga, Michele F.; Dullaart, Robin P. F.; Berger, Stefan P.; Touw, Daan J.; Bakker, Stephan
J. L.; Gaillard, Carlo A. J. M.
Published in:
American Journal of Hematology
DOI:
10.1002/ajh.24785
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Eisenga, M. F., Dullaart, R. P. F., Berger, S. P., Touw, D. J., Bakker, S. J. L., & Gaillard, C. A. J. M. (2017).
Urinary prednisolone excretion is a determinant of serum hepcidin levels in renal transplant recipients.
American Journal of Hematology, 92(8), E173-E175. https://doi.org/10.1002/ajh.24785
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
(Belo Horizonte), Instituto do Ca^ncer do Estado de S~ao Paulo (S~ao
Paulo), Santa Casa de Misericordia de Santos (Santos), Santa Casa de
Misericordia de S~ao Paulo (S~ao Paulo), Universidade Estadual de
Campinas (Campinas), Universidade Estadual de Londrina (Londrina),
Universidade Federal de Goias (Goia^nia), Universidade Federal de
Minas Gerais (Belo Horizonte), Universidade Federal de S~ao Paulo
(S~ao Paulo), Universidade Federal do Ceara (Fortaleza), Universidade
Federal do Parana (Curitiba), Universidade Federal do Rio de Janeiro
(Rio de Janeiro). We would also like to thank Jose Marcio Duarte
and the staff from Departamento de Informatica em Saude - UNIFESP
for providing technical support.
CONFLICT OF INTEREST
The authors have no conflicts of interest to declare.
Matheus Vescovi Gonçalves1 , Celso Arrais Rodrigues1,2 ,
Irene Gyongyver Heidemarie Lorand Metze3,
Marcelo Pitombeira Lacerda1,
Maria de Lourdes Lopes Ferrari Chauffaille1, Alita Azevedo4,
Cintia Machado4, Carlos Sergio Chiattone5,6, Sergio Fortier5,
Leila Perobelli7, Maura Rosane Valerio Ikoma8, Nelma Clementino9,
Nelson Hamerschlak10, Vivia Machado Sthel11,
Larissa Veloso Mendes Ommati12,
Danielle Le~ao Cordeiro de Farias13, Fernando Barroso Duarte14,
Valeria Buccheri15, Ana Paula de Azambuja16,
Denise Ramos de Almeida17, Vera Lucia Piratininga Figueiredo11,
Mihoko Yamamoto1
1Universidade Federal de S~ao Paulo (UNIFESP/EPM), S~ao Paulo, Brazil
2Hospital Sírio Libane^s, S~ao Paulo, Brazil
3University of Campinas, Campinas, Brazil
4Hemocentro de Pernambuco, Hemope, Recife, Brazil
5Santa Casa de Misericordia de S~ao Paulo, S~ao Paulo, Brazil
6Hospital Samaritano, S~ao Paulo, Brazil
7Hospital de Transplantes Euryclides de Jesus Zerbini/Hospital Brigadeiro,
S~ao Paulo, Brazil
8Hospital Amaral Carvalho, Jau, Brazil
9Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
10Hospital Israelita Albert Einstein, S~ao Paulo, Brazil
11Hospital do Servidor Publico Estadual, S~ao Paulo, Brazil
12Casa de Saude Santa Marcelina, S~ao Paulo, Brazil
13Universidade Federal de Goias, Goia^nia, Brazill
14Universidade Federal do Ceara, Fortaleza, Brazil
15Instituto de Cancer de S~ao Paulo, S~ao Paulo, Brazil
16Universidade Federal do Parana, Curitiba, Brazil
17Hospital S~ao Vicente de Paulo, Passo Fundo, Brazil
Correspondence




[1] Pulte D, Castro FA, Jansen L, et al. Trends in survival of chronic lym-
phocytic leukemia patients in Germany and the USA in the first dec-
ade of the twenty-first century. J Hematol Oncol. 2016;9:28
[2] Falchi L, Keating MJ, Wang X, et al. Clinical characteristics, response to
therapy, and survival of African American patients diagnosed with chronic
lymphocytic leukemia: Joint experience of the MD Anderson cancer cen-
ter and Duke university medical center. Cancer. 2013;119:3177–3185.
[3] Vasylyev A, Loginov A, Molostvova V, et al. Prevalence and cumula-
tive 5-year incidence of chronic lymphocytic leukemia in the adult
population in the Russian Federation and Ukraine: Data from the leu-
kospect study. Hematology. 2017;22:16–24.
[4] Wu SJ, Chiang CJ, Lin CT, et al. Improving but inferior survival in
patients with chronic lymphocytic leukemia in Taiwan: A population-
based study, 1990–2004. PLoS One. 2013;8:e62930.
[5] Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis
and treatment of chronic lymphocytic leukemia: A report from the
international workshop on chronic lymphocytic leukemia updating
the national cancer institute-working group 1996 guidelines. Blood.
2008;111:5446–5456.
[6] World Health Statistics 2016: Monitoring health for the SDGs.
http://www.who.int/gho/publications/world_health_statistics/2016/en/
Accessed March 17, 2017.
[7] Mato A, Nabhan C, Kay NE, et al. Real-world clinical experience in
the connect(R) chronic lymphocytic leukaemia registry: A prospective
cohort study of 1494 patients across 199 US centres. Br J Haematol.
2016;175:892–903.
[8] Rodrigues CA, Goncalves MV, Ikoma MR, et al. Diagnosis and treat-
ment of chronic lymphocytic leukemia: Recommendations from the
Brazilian group of chronic lymphocytic leukemia. Rev Bras Hematol
Hemoter. 2016;38:346–357.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting
information tab for this article.
Received: 21 March 2017 | Accepted: 5 May 2017
DOI 10.1002/ajh.24785
Urinary prednisolone
excretion is a determinant of
serum hepcidin levels in renal
transplant recipients
To the Editor:
Hepcidin, which is synthesized and secreted by the liver, is considered
the master regulator of iron homeostasis. Hepcidin regulates the
amount of iron absorbed from the intestines and the iron release
from the reticuloendothelial system by degrading ferroportin, the iron
transporter located at the duodenal enterocytes and macrophages.
Circulating levels of hepcidin are known to be controlled by available
iron stores, inflammation, hypoxia, insulin levels, and erythropoiesis.
.................................................................................
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Recently, hepcidin antagonists have been introduced as potential
treatment to improve iron-restrictive anemia. By improving iron availabil-
ity and subsequently hemoglobin levels, hepcidin antagonists might be
able to improve quality of life and outcome in different patient settings.
Therefore, all factors that affect serum hepcidin levels are clinically rele-
vant specifically in populations where in the future the use of hepcidin
antagonists may be considered. It has already been established that both
testosterone1 and estrogens2 are associated with suppression of serum
hepcidin in men. On the other hand progesterone, the anabolic steroid
epitiostanol, as well as the progesterone antagonist, mifepristone, are
able to induce hepcidin biosynthesis in a zebrafish model.3
Synthetic glucocorticoids, like prednisone, and its active metabolite
prednisolone are often used in immunosuppressive regiments for renal
transplant recipients (RTRs). To date, possible effects of these synthetic
glucocorticoids on serum hepcidin levels in humans are unknown.
Here, we report on the association of serum hepcidin with 24-h urinary
prednisolone excretion, as a measure of 24-h prednisolone exposure.
For this study, 606 stable RTRs with a functioning graft beyond
the first year after transplantation were included.4 All RTRs gave writ-
ten informed consent for the study and approval by institutional review
board was obtained (METc 2001/039). For the current analyses, we
excluded patients with missing data on serum hepcidin (n545) and uri-
nary prednisolone excretion (n510), resulting in 551 RTRs eligible for
analyses. Serum hepcidin-25 was assessed by dual-monoclonal sand-
wich ELISA immunoassay. Urinary prednisolone measurements were
carried out with validated high-performance liquid chromatography
assay with diode-array detection after extraction with diethylether.
Renal function was assessed by estimating glomerular filtration
rate (eGFR) applying the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation.
IBM SPSS Statistics 23 was used for statistical analyses. For baseline
characteristics, one-way ANOVA, Kruskal-Wallis test, and Chi square
test were applied, as appropriate. Furthermore, univariate linear regres-
sion analysis was performed to assess the determinants of serum hepci-
din, followed by multivariable linear regression analysis with stepwise
backward procedure. P values for inclusion and exclusion were set at
0.20 and 0.10, respectively. Variables with a skewed distribution were
natural log transformed for analyses. Separate linear regression analysis
was performed to assess the association between serum hepcidin and
hemoglobin level in RTRs after adjustment for age, sex, and eGFR.
Mean age of the 551 RTRs was 51612years with 55% being
men. Patients were included at median 6.0 (interquartile range [IQR],
2.6–11.6) years after transplantation. All RTRs used prednisolone orally
ranging from 5 to 10mg once daily. Median 24-h urinary prednisolone
excretion was 758 (371–1278) pmol/24h. The association of the
individual daily prednisolone dosis with 24-h urinary prednisolone
excretion was b50.23, P< .001. Across tertiles of 24-h urinary pred-
nisolone excretion, RTRs within the highest tertile of prednisolone
were younger, less frequently men, had lower systolic blood pressure
and higher estimated glomerular filtration rate (eGFR) compared to
those within the other two tertiles. Furthermore, higher hemoglobin,
lower hepcidin, and lower ferritin levels were noted in RTRs in the
highest tertile of prednisolone excretion compared to RTRs in the other
two tertiles (Table 1).
In univariate regression analysis, serum hepcidin was found to be
negatively associated with 24-h urinary prednisolone excretion
(b520.15, P< .001). After adjustment for high-sensitivity C-reactive
protein (hs-CRP), hepcidin remained associated with prednisolone
(b520.13, P5 .002). Further adjustment for eGFR did not materially
alter this association (b520.12, P5 .006). When including predniso-
lone in a backward multivariate model with age, sex, eGFR, hs-CRP,
ferritin, hemoglobin, erythropoietin, and insulin, prednisolone remained
an independent determinant of hepcidin (b520.10, P5 .001), besides
expected relationships of hepcidin with ferritin, hs-CRP, erythropoietin
and insulin. In addition, serum hepcidin was found to be a determinant
of hemoglobin levels (b520.08, P5 .03) independently of age, sex,
and eGFR.
In this study, we show that 24-h urinary prednisolone excretion is
negatively associated with serum hepcidin in RTRs irrespective of poten-
tial confounders, including eGFR. All RTRs in our cohort used a low dose
TABLE 1 Baseline characteristics of 551 renal transplant recipients according to tertiles of 24-h urinary prednisolone excretion
Variables All patients Tertiles of urinary prednisolone excretion (pmol/24 h)
T1 T2 T3 P value
Urinary prednisolone (pmol/24 h) 758 (371–1278) 256 (125–371) 755 (619–904) 1595 (1273–2325) <.001
General characteristics
Age (years) 51 6 12 53 6 12 53 6 12 49 6 12 .003
Male sex (n %) 298 (54) 109 (60) 107 (58) 82 (45) .006
eGFR (mL/min/1.73 m2) 47 6 16 41 6 16 46 6 15 54 6 13 <.001
Laboratory parameters
Hepcidin (ng/mL) 7.2 (3.3–13.5) 8.6 (4.3–14.3) 7.0 (2.8–14.3) 5.8 (2.8–11.4) .003
Hemoglobin (g/dL) 13.8 6 1.6 13.6 6 1.6 13.8 6 1.6 14.2 6 1.4 <.001
Ferritin (g/L) 156.0 (80.0–283.0) 189 (102–316) 163 (77–288) 122 (68–233) .001
EPO (IU/L) 17.4 (12.0–24.3) 17.7 (11.8–25.4) 17.9 (13.0–24.3) 16.6 (11.4–22.9) .28
hs-CRP (mg/L) 2.0 (0.8–4.8) 2.1 (1.0–5.1) 2.7 (0.9–4.8) 1.7 (0.7–3.6) .06
Insulin (mU/mL) 11.1 (7.9–16.3) 11.4 (7.8–17.5) 11.2 (8.3–15.1) 10.8 (7.8–15.8) .53
eGFR, estimated glomerular filtration rate; EPO, erythropoietin; hs-CRP, high sensitivity C-reactive protein.
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prednisolone (5–10mg/day). Remarkably, this resulted in a broad range
of 24-h urinary prednisolone excretion and a modest association with
the daily prednisolone dose, in keeping with considerable inter-subject
pharmacokinetic variability.5 Twenty-4h urinary prednisolone excretion
is considered to reflect the overall exposure to prednisolone. Previously,
it has been shown that prednisolone dose-dependently inhibits the
release of interleukin-6 (IL-6)6 which is known to induce hepcidin
expression. We had no data available on IL-6 levels to assess whether
effects on IL-6 is the mechanism behind the association of prednisolone
with hepcidin. The possible role of prednisolone as a direct hepcidin
antagonist and possible mechanisms linking prednisolone with hepcidin
need to be delineated in more detail in future studies.
The major strength of this report is the large cohort of RTRs with
availability of concurrent 24-h urinary prednisolone excretion and hep-
cidin data. Limitations are that it comprises a single center study, and
that we cannot exclude the possibility of residual confounding.
In conclusion, lower serum hepcidin levels are related to higher
24-h urinary prednisolone excretion in RTRs independent of clinically
relevant covariates. Our findings extend earlier data concerning effects
of other (synthetic) steroids on hepcidin regulation, and provide a
rationale to more precisely delineate direct or indirect effects of gluco-
corticoids on hepcidin regulation. From a clinical perspective, our find-
ings lend support to the possibility that prednisolone may be regarded
as a hitherto unappreciated hepcidin antagonist.
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Characterization of TP53
mutations in clonal cytopenia
of undetermined significance
To the Editor:
The diagnosis of myelodysplastic syndrome (MDS) requires persis-
tent cytopenia with at least one of the following criteria: dysplasia in
at least 10% of cells in any hematopoietic lineage, increased myelo-
blasts (5–19%) in bone marrow (or 2–19% myeloblast in peripheral
blood), or MDS defining cytogenetic abnormalities. Some patients
have cytopenia and/or gene mutations, but do not meet other crite-
ria of MDS.1 These pre-MDS conditions include idiopathic cytopenia
of undetermined significance (ICUS), clonal hematopoiesis of inde-
terminate potential (CHIP) and clonal cytopenia of undetermined
significance (CCUS). The mutations frequently identified in these
pre-MDS conditions, including DNMT3A, TET2, and ASXL1, are also
the common mutations detected in MDS.2 ICUS, CHIP, and CCUS all
carry an increased risk for progression to MDS. The rate of progres-
sion to MDS varies, likely depending on the specific genes that are
mutated and their mutation burden. The role of each individual
mutation in disease progression is not well characterized.
TP53 is a tumor suppressor gene that has been studied extensively
in MDS and AML, in which the mutations are associated with a
complex karyotype and a poor prognosis. Its mutations also occur in
CHIP and CCUS.2,3 The characteristics of TP53 mutations and their
role in disease progression in these pre-MDS conditions are unknown.
In this study, we aim to characterize the clinicopathological features of
CCUS cases associated with TP53 mutations.
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